MiNA Therapeutics presents positive Phase 1b data on MTL-CEBPA in combination with anti-PD1 checkpoint inhibitor 11 Nov, 2022 MiNA Therapeutics presents proof of mechanism data on MTL-STING as a novel cancer immunotherapy 11 April, 2022 First patient dosed in randomised Phase 2 clinical trial of MTL-CEBPA in patients with advanced liver cancer 25 January, 2022 MiNA Therapeutics appoints two Independent Directors with extensive industry experience to support next phase of growth 21 December, 2021


Harnessing the innate mechanism of gene activation, MiNA Therapeutics’ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases.


Small activating RNAs are an entirely new class of medicines with potential to offer transformational benefits to patients across a wide range of diseases.


We have developed a systematic approach to take new saRNA medicines from an idea to patients in a clinical trial in just 2 years.


Driving our platform are a group of passionate scientists, drug developers, doctors and entrepreneurs shaped by experience in oligonucleotide therapeutics, oncology and immunology.

By continuing to use this site you are agreeing only to the use of cookies that are strictly necessary for the running of our website. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.